We observed the TAM assessment in SCCHN is mainly based on IHC expression on FFPE-tissue material while using a restricted set of monoclonal staining antibodies (mostly CD68 and CD163). The gene discussed is CD163; the disease is head and neck squamous cell carcinoma.